It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Eosinophils are a group of granulocytes well known for their capacity to protect the host from parasites and regulate immune function. Diverse biological roles for eosinophils have been increasingly identified, but the developmental pattern and regulation of the eosinophil lineage remain largely unknown. Herein, we utilize the zebrafish model to analyze eosinophilic cell differentiation, distribution, and regulation. By identifying eslec as an eosinophil lineage-specific marker, we establish a Tg(eslec:eGFP) reporter line, which specifically labeled cells of the eosinophil lineage from early life through adulthood. Spatial-temporal analysis of eslec+ cells demonstrates their organ distribution from larval stage to adulthood. By single-cell RNA-Seq analysis, we decipher the eosinophil lineage cells from lineage-committed progenitors to mature eosinophils. Through further genetic analysis, we demonstrate the role of Cebp1 in balancing neutrophil and eosinophil lineages, and a Cebp1-Cebpβ transcriptional axis that regulates the commitment and differentiation of the eosinophil lineage. Cross-species functional comparisons reveals that zebrafish Cebp1 is the functional orthologue of human C/EBPεP27 in suppressing eosinophilopoiesis. Our study characterizes eosinophil development in multiple dimensions including spatial-temporal patterns, expression profiles, and genetic regulators, providing for a better understanding of eosinophilopoiesis.
Eosinophils are innate immune cells critical for protection from parasites, but their developmental origin remains under studied. Here they analyze development of eosinophils in zebrafish and find that eosinophilic lineage commitment and differentiation are regulated by the Cebp1-Cebpβ axis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 South China University of Technology, Department of Hematology, the Second Affiliated Hospital, School of Medicine, Guangzhou, P.R. China (GRID:grid.79703.3a) (ISNI:0000 0004 1764 3838); South China University of Technology, Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, Guangzhou, P.R. China (GRID:grid.79703.3a) (ISNI:0000 0004 1764 3838)
2 South China University of Technology, Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, Guangzhou, P.R. China (GRID:grid.79703.3a) (ISNI:0000 0004 1764 3838)
3 A*STAR (Agency for Science, Technology and Research), Singapore Immunology Network (SIgN), Biopolis, Singapore (GRID:grid.430276.4) (ISNI:0000 0004 0387 2429)
4 Southern Medical University, Department of Developmental Biology, School of Basic Medical Sciences, Guangzhou, P.R. China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
5 Shanghai JiaoTong University School of Medicine, Shanghai Institute of Immunology, Shanghai, P.R. China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)
6 Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P.R. China (GRID:grid.488530.2) (ISNI:0000 0004 1803 6191)
7 A*STAR (Agency for Science, Technology and Research), Singapore Immunology Network (SIgN), Biopolis, Singapore (GRID:grid.430276.4) (ISNI:0000 0004 0387 2429); Shanghai JiaoTong University School of Medicine, Shanghai Institute of Immunology, Shanghai, P.R. China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)
8 A*STAR (Agency for Science, Technology and Research), Singapore Immunology Network (SIgN), Biopolis, Singapore (GRID:grid.430276.4) (ISNI:0000 0004 0387 2429); Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai Immune Therapy Institute, Shanghai, P.R. China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293); National University of Singapore, Department of Microbiology and Immunology, Immunology Translational Research Program, Yong Loo Lin School of Medicine, Immunology Program, Life Sciences Institute, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)